伤寒Vi多糖菌苗免疫血清的LPS抗体测定

以肠炎沙门氏菌脂多糖为抗原,用酶标法测定Ｖｉ多糖菌苗免疫血清的抗ＬＰＳ抗体。各Ｖｉ多糖菌苗组免疫后１月,６月的抗ＬＰＳ水平均显著高于免前（Ｐ＜０．０００１）,对照组无显著差异（ｐ＞０．１）。两３０μｇ菌苗组抗ＬＰＳ阳转率均约为１５％。提纯Ｖｉ多糖菌苗所含的微量伤寒ＬＰＳ,也可能为接种者提供一定的保护作用。     

甘肃张掖地区小学生丙型肝炎病毒感染情况的调查研究

用ＥＬＩＳＡ法检测了甘肃张掖地区２８４名小学生血清中抗－ＨＣＶ,阳性率为２．８％（８／２７６）。与北京、深圳、南京、青岛等地比较证实,除与青岛地区自然人群抗－ＨＣＶ阳性率有显著性差异外（ｘ２＝６．５,０．０１＜ｐ＜０．０５）,与其它地区均无显著性差异（Ｐ＞０．０５）。     

不同月龄婴儿接种DTP后血清中百日咳抗体水平的观测

本文对比观察了２１３例２月龄、３月龄婴儿接种ＤＴＰ后百日咳抗体水平的变化,探讨了母传抗体对免后抗体增长的影响。结果表明２月龄、３月龄婴儿ＤＴＰ免疫后１个月和３个月血清中百日咳抗体达保护水平的百分率无显著性差异（ｘ￣２＝０．０３６,ｐ＞０．９;ｘ￣２＝０．３２７,ｐ＞０．５）,免后１个月抗体ＧＭＴ无显著性差异（ｔ＝０．１７,ｐ＞０．５）,免后３个月抗体ＧＭＴ３月龄组高于２月龄组（ｔ＝２．２２,ｐ＜０．０５）。我们还发现免前抗体水平与免后１个月ＧＭＴ虽有负相关（ｒ＝—０,７５４）的倾向,但总体上对抑制免后抗体应答不明显,因而建议将儿童ＤＴＰ基础免疫的起始月龄提前至２月龄进行。     

联合应用生态制剂治疗感染性腹泻的临床研究

本文应用丽珠肠乐加整肠生联合治疗感染性腹泻,治愈率为９２．１％,与单一应用整肠生,治愈率（７３．１％）有显著性差异（ｘ￣２＝４．２４,Ｐ＜０．０５）,与氟哌酸组无明显差异（ｘ￣２＝３．０２,Ｐ＞０．０５）,单一整肠生组与氟哌酸组无明显差异（ｘ￣２＝０．２２,Ｐ＞０．０５）。生态制剂有良好确切疗效,两种生态制剂联合治疗,明显提高治愈率。感染性腹泻原因菌的分离结果,揭示了本地区感染性腹泻病原菌的多样化和复杂性,应用生态制剂联合治疗,优于抗生素治疗。     

伤寒Vi多糖菌苗多糖含量及分子大小测定试验

伤寒Ｖｉ多糖菌苗是我国新近研制成功的一种多糖菌苗。为了严格控制该制品的质量,经反复试验,建立了多糖含量和分子大小的测定方法。本文报导了（１）用火箭电泳法测定伤寒Ｖｉ多糖菌苗多糖含量。经对不同实验条件进行比较,选择出较为理想的条件。用该法测定８批样品。结果均符合规程要求。对其中５批样品进行６次重复试验表明,该法的重复性好,操作简单,是测定多糖含量较为理想的方法。（２）用琼脂糖柱层析法对２８批伤寒Ｖｉ多糖菌苗的分子大小进行测定。对用该法所得柱层析收集液分别用Ｈｅｓｔｒｉｎ法和２０６ｎｍ扫描法测定其多糖回收率,对测定结果进行比较。结果表明,两种方法的测定结果无显著性差异（Ｐ＞０．０１）,而且重复性均好。可根据实验室条件选择测定方法。     

维生素A缺乏胎鼠作为先天性心脏病动物模型的实验研究

目的　探讨将维生素Ａ缺乏（ＶＡＤ）胎鼠作为先天性心脏病动物模型的可行性。方法取１１－１９ｄ不同胎龄正常及ＶＡＤ胎鼠心脏经石蜡包埋、切片及 ＨＥ染色观察其发育情况。结果 １．实验组饲料含维生素Ａ（ＶＡ）７μｇ／１００ｇ,经ＶＡＤ饮食喂养后实验组大鼠血清ＶＡ水平明显低于对照组［（０．１６８±０．０５９）μｍｏｌ／Ｌ Ｖｓ（２．１８±０．２３）μｍｏｌ／Ｌ,ｔ＝３２．８８, Ｐ＜０．００１］。 ２．大鼠死亡百分比：饲养于屏障系统的ＶＡＤ大鼠死亡百分比较饲养于开放系统中的要低４．６倍（１０％ Ｖｓ ４５．８３％．ｘ ２＝１６．６４, Ｐ＜０．００１）,对照组为０。 ３．实验组大鼠受孕百分比及每只孕鼠产仔数均低于对照组［５８．３３％ Ｖｓ ８１．５％, ｘ ２＝４．３７,Ｐ＜０．０５：（６．９７±２．７９） Ｖｓ（１３ ±１．０５）,ｔ＝７．１６, Ｐ＜０．００１］。 ４．经切片观察１１～１５ ｄ胎龄胎鼠实验组心脏出现明显发育延迟的占３６．６７％, １６～１９ ｄ胎龄胎鼠实验组心脏畸形占４１．４３％,血管异常占１８．５７％。结论ＶＡＤ胎鼠可用来作为先天性心脏病动物模型,但需改进饲养环境以减少异常死亡。     

伤寒Vi多糖疫苗大规模生产中的工艺改进

对伤寒Ｖｉ多糖疫苗大规模生产进行了三项工艺改进：１．将液体菌种由静止期接种大罐改为对数生长期接种大罐,大罐培养时间可缩短３－４小时。２．２％（Ｖ／Ｖ）甲醛溶液杀菌时间由５℃６小时改为２０－２５℃２小时,能保证杀菌完全。３．用冷酚精制Ｖｉ多糖由常规法改为乳化法,可减少精制次数及冷酚用量,提高多糖收率     

正常足月儿畸变产物耳声发射(DPOAEs)特性分析

研究提出正常足月儿畸变产物耳声发射（ＤＰＯＡＥｓ） 特性分析如下：１ ． ＤＰＯＡＥｓ 反应强度曲线,ＤＰ 图显示两个反应峰（ｆ２ ＝ １ ．６ 和５ ．０ ｋＨｚ） 和一个反应谷（ｆ２ ＝ ３ ．１ ～４ ．０ ｋＨｚ） ;２． ＤＰＯＡＥ 本底噪声及其特性,ｆ２ ＝ １．０ ｋＨｚ 其测试频率点（２ｆ１ －ｆ２） 本底噪声最高（Ｐ＜ ０ ．０５） ,ｆ２ ＝ ３ ．１ ,４．０ 和５ ．０ｋＨｚ ,测试频率点（２ｆ１ －ｆ２） 本底噪声较低（Ｐ＜ ０．０５） ;除ｆ２ ＝ ４．０ ｋＨｚ 外,ＤＰＯＡＥ 本底噪声与其反应强度均未呈现直线相关特性;３ ． ＤＰＯＡＥ ＳＮＲ 特性,ｆ２ ＝ １．０ ｋＨｚ 其ＳＮＲ 最小（Ｐ＝ ０．０００） ,ｆ２ ＝２ ．０ ｋＨｚ 其ＳＮＲ 最大（Ｐ０ ．００３） ;４． ＤＰＯＡＥ ＳＮＲ 和ＴＥＯＡＥ ＳＮＲ 相关特性,除１．０ ｋＨｚ 频段外,其余频段其二者间均有着非常显著的直线相关特性。     

植物微核技术在监测水质污染中的应用

应用韭菜微核技术,检测哈尔滨市量具刃具厂含铬废水的遗传毒性,试验表明：含铬废水可诱导韭菜和蚕豆根尖细胞产生微核,进行回归分析,其蚕豆对Ｃｒ＾＋６诱变剂回归分析为ｙ＝２４．９４＋１２７．７７ｘ（ｒ＝０．９９６,Ｐ〈０．０１）,韭菜对Ｃｒ＾＋６诱变剂回归广泛为：ｙ＝２１．７４＋１００．２３ｘ（ｒ＝０．９００,Ｐ〈０．０１）,ｒ＝１１．１７＋３．３８ｘ（ｒ＝０．７８１,Ｐ〈０．０５）,韭菜根尖微核技术具     

国产重组酵母乙型肝炎疫苗接种小学生的3年免疫效果观察

本文报告对２５８ 名小学生应用０、１、６ 月程序,接种２ 批国产酵母疫苗（５ μｇ／０．５ ｍ ｌ）,１ 批Ａｍ ｇｅｎ 酵母疫苗（１０ μｇ／ｍ ｌ）,１ 批Ｍ ＳＤ 酵母疫苗（５ μｇ／０．５ ｍ ｌ）的小学生免后３ 年（（Ｔ３６）效果观察。结果表明,Ｔ３６ 时抗体 ＧＭＴ（几何平均滴度）,Ａｍ ｇｅｎ 疫苗组（１４５．７５）显著高于 ２ 批国产疫苗（９２．１１、８３．５２）和Ｍ．Ｓ．Ｄ 苗组（７４．６２）,抗体ＧＭＴ 峰值显著低于Ａｍ ｇｅｎ 和Ｍ ．Ｓ．Ｄ 苗的２ 批国产酵母疫苗,与Ｍ．Ｓ．Ｄ 苗抗体ＧＭＴ 水平无显著差异（Ｐ＞ ０．０５）。抗体阳转率间各疫苗组均无显著差异（９３．１０％ ～７４．１４％ ）。本次随访结果表明,采用０,１,６ 免疫程序,国产酵母疫苗免后３ 年的抗体阳转率和抗体ＧＭＴ水平不低于进口同类酵母疫苗的水平。     

Immunological response of three mouse strains to typhoid vaccine and Vi antigen

Vi-agglutinin, active cutaneous anaphylaxis and protective responses (ed(50)) of three mouse strains (CFW, NIH, and Balb/cAnN) to acetone-inactivated typhoid vaccine and soluble Vi antigen were compared. Seven days after immunization with either typhoid vaccine or Vi antigen the three strains of mice differed with respect to Vi-antibody titers. Significant differences were observed in the protective responses. Each mouse strain was significantly better protected by the intraperitoneal than by subcutaneous route of immunization. Active cutaneous anaphylaxis was more pronounced in showing strain differences in response to Vi antigen. The serological responses to Vi antigen of the strains of mice did not correlate with their protective response.     

Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea

The purpose of this study was to evaluate the immunogenicity and safety of Salmonella Typhi Vi capsular polysaccharide vaccine (Vi vaccine) in Korea. The immunogenicity of a single dose of Vi vaccine was evaluated in 157 subjects (75 children and 82 adults) before and at 1, 6, and 12 months after vaccination. Immunogenicity was measured with a passive hemagglutination assay (PHA), quantified as geometric mean titers (GMTs) and seroconversion rates. The safety of the vaccine was investigated by determining adverse reactions occurring within 4 h, 3 days, and 1 month after injection. The seroconversion rate for children and adults 1 month after vaccination was 96.92% and 89.02%, respectively. In the case of children, the GMTs of Vi antibodies before vaccination were 5.87 +/- 1.34 and 142.59 +/- 2.39 at one month after vaccination. For adults, the GMTs before and one month after vaccination were 5.58 +/- 1.28 and 58.56 +/- 3.67, respectively. Vi antibodies persisted for as long as 6 and 12 months after vaccination. All adverse reactions in adults and children were minor and did not require treatment. The Vi CPS vaccine was safe and immunogenic in adults and children older than 5 years.     

伤寒Vi多糖结合疫苗免疫小鼠后的抗体类型及动态分析

伤寒Vi多糖结合疫苗和Vi多糖疫苗分别免疫小鼠,分离血清,采用间接ELISA法测定不同时点血清中特异性IgA、IgM、IgG及其亚类(IgG1、IgG2a、IgG3)的抗体滴度。结果显示,免疫一针后,Vi多糖结合疫苗组的IgG抗体GMT值明显升高,第二针有加强效应(P<0.01);所测3种IgG亚型中IgG2a抗体滴度升高明显;Vi多糖和结合疫苗免疫小鼠后,血清中IgA和IgM抗体滴度均有显著升高,但无加强应答。显示Vi多糖结合疫苗在诱导小鼠血清IgG应答方面有加强效应。     

O139型霍乱菌苗人群副反应观察报告

在广西田阳县中学生中,分６组共６９７人进行了Ｏ１３９型霍乱菌苗与Ｏ１群霍乱菌苗的双盲、有对照的人体反应现场观察。结果表明,不加铝佐剂的Ｏ１３９型霍乱菌苗及Ｏ１群霍乱菌苗,不论是低剂量组（两剂全程接种４５亿菌体）抑或常剂量组（全程接种９０亿）接种人群均可产生１０～２５％的体温呈轻度升高的弱反应,并且同种菌苗的两剂量组的反应率无显著差异;第一剂接种的反应率（１９～２５％）较第二剂接种的（１０～１５％）高,Ｐ＜０．０５;接种局部反应轻微,只有个别受试者出现直径小于１５ｍｍ的硬结;加佐剂的Ｏ１群吸附霍乱菌苗的反应较其它组强。结果证实,甲醛灭活的Ｏ１３９型霍乱菌苗和Ｏ１群霍乱菌苗是安全的,接种人体对之具有良好的耐受性     

Immunization of arctic foxes (Alopex lagopus) with oral rabies vaccine

Arctic foxes (Alopex lagopus) were successfully immunized against rabies using an orally-administered, liquid SAD-BHK21 live virus vaccine in a sausage bait. Immunization was determined by serologic response and by resistance to challenge with an arctic rabies virus strain. Virus was not shed in saliva following oral vaccination, indicating that arctic foxes would not infect other foxes after ingesting this vaccine. High antibody levels were present in all experimental foxes 2 wk following initial vaccination. A booster vaccination at 56 wk induced a significant serologic response within 1 wk, suggesting an anamnestic response but titers began to decline within 8 wk in most foxes. Foxes were observed for 16 mo following the challenge and exhibited no symptoms of rabies. The SAD-BHK21 rabies vaccine in a sausage bait system has a strong potential for vaccinating wild populations of arctic fox.     

流行性出血热(EHF)Ⅱ型(家鼠型)纯化灭活疫苗Ⅰ期临床观察

根据卫生部(91)特申体第02号文,92年完成了Ⅱ型纯化疫苗Ⅰ期临床反应及血清效果观察,免疫程序为0,1,2月,分原倍疫苗组和1∶2稀释组,各免15人,每针次免疫后连续观察3天,结果均无不良反应,仅在注射时稍有微胀痛感。二针次免疫后均能产生较高的免疫抗体:原倍疫苗免疫抗体滴度,ELISA1∶181(GET),PRNT中和抗体≥1∶10;1∶2稀释疫苗,ELISA1∶169(GMT),PRNT≥1∶10。三针次免疫后抗体滴度高于二针次;原倍疫苗,ELISA1∶478(GMT),PRNT1∶10～1∶20;稀释疫苗,ELISA1∶446(GMT),PRNT1∶10～1∶20,但原倍疫苗和稀释疫苗的抗体水平之间无显著性差异。半年后仍保持一定抗体水平。可采用二针次总量2ml免疫。     

Correlative Gene Expression to Protective Seroconversion in Rift Valley Fever Vaccinates

Rift Valley fever Virus (RVFV), a negative-stranded RNA virus, is the etiological agent of the vector-borne zoonotic disease, Rift Valley fever (RVF). In both humans and livestock, protective immunity can be achieved through vaccination. Earlier and more recent vaccine trials in cattle and sheep demonstrated a strong neutralizing antibody and total IgG response induced by the RVF vaccine, authentic recombinant MP-12 (arMP-12). From previous work, protective immunity in sheep and cattle vaccinates normally occurs from 7 to 21 days after inoculation with arMP-12. While the serology and protective response induced by arMP-12 has been studied, little attention has been paid to the underlying molecular and genetic events occurring prior to the serologic immune response. To address this, we isolated RNA from whole blood of vaccinated calves over a time course of 21 days before and after vaccination with arMP-12. The time course RNAs were sequenced by RNASeq and bioinformatically analyzed. Our results revealed time-dependent activation or repression of numerous gene ontologies and pathways related to the vaccine induced immune response and its regulation. Additional bioinformatic analyses identified a correlative relationship between specific host immune response genes and protective immunity prior to the detection of protective serum neutralizing antibody responses. These results contribute an important proof of concept for identifying molecular and genetic components underlying the immune response to RVF vaccination and protection prior to serologic detection.